BMI1
| | | [1]
|---|---| [2]
| Full Name | BMI1 Proto-Oncogene, Polycomb Ring Finger | [3]
| Gene Symbol | BMI1 | [4]
| Aliases | PCGF4, RNF51, FLVI2 | [5]
| Chromosome | 10p12.2 | [6]
| Gene Type | Protein-coding | [7]
| OMIM | 164831 | [8]
| UniProt | P35226 |
| HGNC | 1048 |
| Entrez Gene | 648 |
| Ensembl | ENSG00000168283 |
BMI1 is a human gene. Variants in BMI1 have been implicated in Alzheimer's Disease, Parkinson's Disease, Huntington's Disease. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
BMI1 (B lymphoma Mo-MLV insertion region 1 homolog), also designated PCGF4 or RNF51, encodes a core component of the Polycomb Repressive Complex 1 (PRC1). BMI1 functions as the central E3 ubiquitin ligase cofactor that stimulates RNF2-mediated monoubiquitination of histone H2A at lysine 119 (H2AK119ub1), a histone modification essential for Polycomb-mediated transcriptional silencing.[1] In the nervous system, BMI1 is critical for neural stem cell self-renewal, cerebellar development, and long-term maintenance of neuronal identity. Declining BMI1 expression during aging contributes to heterochromatin erosion, reactivation of senescence programs, and neurodegeneration in Alzheimer's disease and Parkinson's disease.
BMI1 contains an N-terminal RING finger domain and a central helix-turn-helix-turn-helix (HTHTX) domain. The RING domain heterodimerizes with RNF2 (RING1B) to form the catalytic core of canonical PRC1 (cPRC1), dramatically enhancing RNF2 E3 ubiquitin ligase activity toward H2AK119.
BMI1-RNF2 forms the enzymatic module of canonical PRC1. This heterodimer is recruited to chromatin through interactions with CBX proteins (CBX2/4/6/7/8), which read EED/SUZ12-containing PRC2-deposited H3K27me3 marks. The sequential action of PRC2 (H3K27me3 writing) followed by PRC1 (H2AK119ub1 writing) establishes stable transcriptional repression at developmental gene loci. BMI1 stimulates RNF2 catalytic activity approximately 10-fold, making it essential for efficient H2AK119ub1 deposition.[1]
BMI1 is essential for self-renewal of neural stem cells (NSCs) in the subventricular zone (SVZ) and hippocampal dentate gyrus. BMI1 represses the Ink4a/Arf locus (CDKN2A), preventing premature senescence and maintaining the proliferative capacity of neural progenitors. Bmi1-null mice exhibit progressive postnatal cerebellar degeneration and depletion of NSC pools.[2]
Beyond its canonical PRC1 role, BMI1 contributes to heterochromatin integrity at repetitive elements and satellite DNA. BMI1 cooperates with SUV39H1 and HP1α/CBX5 to maintain repressive chromatin states. Loss of BMI1 leads to global heterochromatin relaxation, derepression of retrotransposons, and activation of DNA damage responses.[7]
BMI1 confers protection against oxidative stress through multiple mechanisms. It represses pro-oxidant genes while maintaining mitochondrial function. BMI1-deficient neurons show increased reactive oxygen species (ROS), mitochondrial dysfunction, and sensitivity to oxidative damage.[3]
BMI1 expression is significantly reduced in Alzheimer's disease cortical neurons. This downregulation correlates with loss of H2AK119ub1 at gene regulatory regions, derepression of beta-secretase BACE1, increased amyloid-beta production, and tau hyperphosphorylation. Conditional BMI1 knockout in adult mouse neurons recapitulates key AD pathological features including amyloid plaques, neurofibrillary tangles, and neuronal loss.[4]
In Parkinson's disease, BMI1 reduction in dopaminergic neurons of the substantia nigra is associated with impaired oxidative stress responses and mitochondrial dysfunction. BMI1 haploinsufficiency accelerates alpha-synuclein aggregation and dopaminergic neurodegeneration in mouse models.[5]
Huntington's disease striatal neurons show redistributed PRC1 complexes with altered BMI1-RNF2 chromatin occupancy. Mutant huntingtin protein interferes with PRC1 targeting, leading to derepression of non-neuronal genes and loss of striatal neuronal identity.
BMI1 is a key determinant of organismal aging rate. BMI1 expression declines with age in human cortex, correlating with accumulation of senescence markers, increased Ink4a/Arf expression, and reduced neurogenesis. This age-dependent BMI1 decline creates a permissive environment for neurodegenerative disease onset.[7]
BMI1 is highly expressed in the developing and adult central nervous system, with enrichment in neural stem cell niches (SVZ, hippocampus), cerebellar Purkinje cells, cortical pyramidal neurons, and substantia nigra dopaminergic neurons. Expression is highest during embryonic neurogenesis and progressively declines with aging. In microglia, BMI1 restrains inflammatory gene activation by maintaining repressive chromatin states at cytokine promoters.
| Variant | Type | Association | Reference |
|---|---|---|---|
| rs7900170 | Intronic | AD risk (GWAS suggestive) | El Hajj et al., 2019 |
| BMI1 promoter methylation | Epigenetic | Reduced expression in AD cortex | Flamier et al., 2018 |
Liu et al. Bmi1 regulates mitochondrial function and the DNA damage response pathway (2009). 2009. ↩︎
Flamier et al. Modeling late-onset sporadic Alzheimer's disease through BMI1 deficiency (2018). 2018. ↩︎
Chatoo et al. The polycomb group gene Bmi1 regulates antioxidant defenses in neurons (2009). 2009. ↩︎
El Hajj et al. Epigenetic dysregulation in the developing Down syndrome cortex (2019). 2019. ↩︎
Abdouh et al. BMI1 is down-regulated in the aging brain and displays antioxidant and protective activities in neurons (2012). 2012. ↩︎
Gao et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes (2012). 2012. ↩︎
Zencak et al. Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation (2005). 2005. ↩︎
Vonhoff et al. Polycomb group genes in Drosophila neurons (2012). 2012. ↩︎